1|Page
NAMS MENOPAUSE CERTIFICATION EXAM LATEST 2026-2027
ACTUAL EXAM WITH COMPLETE QUESTIONS AND CORRECT
DETAILED ANSWERS (100% VERIFIED ANSWERS) |ALREADY
GRADED A+| ||PROFESSOR VERIFIED|| ||BRANDNEW!!!||
Rate of fat gain doubles and lean mass declines during
menopausal transition; when do things stabilize? - ANSWER-
about 2 years after FMP
Weight gain during menopausal transition - ANSWER-2-4 fold
increase in fat mass (6%, 1.6kg over 3.5 years
.5% loss of lean muscle
Changes in weight gain during peri/meno - ANSWER-
Premenopaust weight increase,MT - stead increase, post meno
no change
Should calorie intake decrease in post menopause - ANSWER-
yes likely driven by decreased active energy expenditure
HRT on cardiovascular risk factors - ANSWER-IN women w/o DM,
HRT (oral or transdermal E+/-P) improves lean body mass,
,2|Page
reduces abdominal adiposity, improves insulin resistance,
improves lipids, decreases BP
When to add anti-obesity medication - ANSWER-Initiate weight
loss medication as adjunct to lifestyle:
- if BMI (27-29.9 in presence of comorbid)
- If BMI >30 and failure of lifestyle
Weight loss w/ orlistat - ANSWER-~8%
GI lipase inhibitor
Poop in your pants
Weight loss with phentermine/topiramate ER - ANSWER-8-12%
C/I: glaucoma, hyperthyroid, MAOI
SE: insomnia, dry mouth, paresthesias, metabolic acidocis,
anxiety, tachy
Weight loss with Naltrexone SR/Bupropion SR (Contrave) -
ANSWER-~5-6.4%
,3|Page
Dopamine and norepinephrine reuptake inhibitor and u-opioid
receptor antagonist
C/I: htn, seizures, eating disorder, opioid use,
SE: nausea, headache
Weight loss with liraglutide - ANSWER-GLP-1 receptor agonist
Dose up to 3mg daily in .6mg steps
Weight loss ~7-10%
C/I: pancreatitis, fam hx of medullary thyroid, multiple endocrine
neoplasia
S/E: nausea, diarrhea, vomiting constipation
Weight loss with semaglutide - ANSWER-~14-16%
GLP-1 receptor agonist
Dose up yo 2.4mg daily in slow weekly dose titration
C/I: pancreatitis, fam hx of medullary thyroid, multiple endocrine
neoplasia
S/E: nausea, diarrhea, vomiting constipation
, 4|Page
Climacteric phase - ANSWER-The period of endrocrinologic,
somatic, and transitory psychologic changes that occur around
the time of menopause.
Early menopause - ANSWER-LMP before age 45
Late menopause - ANSWER-LMP after age 54
Primary ovarian insufficiency - ANSWER-Menopause that occurs
before age 40
Early menopause transition (stage -2) - ANSWER-Persistent
difference of 7 days or more in the length of consecutive cycles.
Late menopause transition (stage -1) - ANSWER-60 or more
consecutive days of amenorrhea
Luteal out of phase event (LOOP) - ANSWER-Explains why some
perimenopausal women have elevated estrogen level
sometimes...In the early menopause transition, elevated FSH
NAMS MENOPAUSE CERTIFICATION EXAM LATEST 2026-2027
ACTUAL EXAM WITH COMPLETE QUESTIONS AND CORRECT
DETAILED ANSWERS (100% VERIFIED ANSWERS) |ALREADY
GRADED A+| ||PROFESSOR VERIFIED|| ||BRANDNEW!!!||
Rate of fat gain doubles and lean mass declines during
menopausal transition; when do things stabilize? - ANSWER-
about 2 years after FMP
Weight gain during menopausal transition - ANSWER-2-4 fold
increase in fat mass (6%, 1.6kg over 3.5 years
.5% loss of lean muscle
Changes in weight gain during peri/meno - ANSWER-
Premenopaust weight increase,MT - stead increase, post meno
no change
Should calorie intake decrease in post menopause - ANSWER-
yes likely driven by decreased active energy expenditure
HRT on cardiovascular risk factors - ANSWER-IN women w/o DM,
HRT (oral or transdermal E+/-P) improves lean body mass,
,2|Page
reduces abdominal adiposity, improves insulin resistance,
improves lipids, decreases BP
When to add anti-obesity medication - ANSWER-Initiate weight
loss medication as adjunct to lifestyle:
- if BMI (27-29.9 in presence of comorbid)
- If BMI >30 and failure of lifestyle
Weight loss w/ orlistat - ANSWER-~8%
GI lipase inhibitor
Poop in your pants
Weight loss with phentermine/topiramate ER - ANSWER-8-12%
C/I: glaucoma, hyperthyroid, MAOI
SE: insomnia, dry mouth, paresthesias, metabolic acidocis,
anxiety, tachy
Weight loss with Naltrexone SR/Bupropion SR (Contrave) -
ANSWER-~5-6.4%
,3|Page
Dopamine and norepinephrine reuptake inhibitor and u-opioid
receptor antagonist
C/I: htn, seizures, eating disorder, opioid use,
SE: nausea, headache
Weight loss with liraglutide - ANSWER-GLP-1 receptor agonist
Dose up to 3mg daily in .6mg steps
Weight loss ~7-10%
C/I: pancreatitis, fam hx of medullary thyroid, multiple endocrine
neoplasia
S/E: nausea, diarrhea, vomiting constipation
Weight loss with semaglutide - ANSWER-~14-16%
GLP-1 receptor agonist
Dose up yo 2.4mg daily in slow weekly dose titration
C/I: pancreatitis, fam hx of medullary thyroid, multiple endocrine
neoplasia
S/E: nausea, diarrhea, vomiting constipation
, 4|Page
Climacteric phase - ANSWER-The period of endrocrinologic,
somatic, and transitory psychologic changes that occur around
the time of menopause.
Early menopause - ANSWER-LMP before age 45
Late menopause - ANSWER-LMP after age 54
Primary ovarian insufficiency - ANSWER-Menopause that occurs
before age 40
Early menopause transition (stage -2) - ANSWER-Persistent
difference of 7 days or more in the length of consecutive cycles.
Late menopause transition (stage -1) - ANSWER-60 or more
consecutive days of amenorrhea
Luteal out of phase event (LOOP) - ANSWER-Explains why some
perimenopausal women have elevated estrogen level
sometimes...In the early menopause transition, elevated FSH
